Pfizer gets new rebuff from NICE for cancer drug
LONDON (Reuters) - Pfizer suffered a second rejection in two days from health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service.
The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources.
The decision follows a similar rebuff for Pfizer's lung cancer drug Xalkori on Wednesday.
In both cases, the NICE recommendations are preliminary and subject to further consultation.
- Tweet this
- Share this
- Digg this
- Exclusive - Over 100 Russian soldiers killed in single Ukraine battle - Russian rights activists
- Scotland's pro-independence campaign gains on final TV debate - poll
- Russia says military planning will take account of NATO moves on borders
- Analysis - Bitcoin shows staying power as online merchants chase digital sparkle
- U.S. openly accuses Russia of sending combat troops to Ukraine